Centessa Pharmaceuticals (NASDAQ:CNTA) Price Target Raised to $28.00

Centessa Pharmaceuticals (NASDAQ:CNTA) had its price objective raised by Guggenheim from $24.00 to $28.00 in a research report released on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Several other equities research analysts also recently commented on CNTA. B. Riley started coverage on Centessa Pharmaceuticals in a report on Thursday, September 19th. They set a “buy” rating and a $33.00 target price for the company. Oppenheimer reaffirmed an “outperform” rating and set a $14.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday, August 14th. BMO Capital Markets upped their target price on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a report on Monday, September 16th. Jefferies Financial Group upped their price target on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Finally, Morgan Stanley raised Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $11.00 to $26.00 in a research report on Thursday, September 19th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Centessa Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $25.83.

Centessa Pharmaceuticals Trading Up 0.6 %

Shares of Centessa Pharmaceuticals stock opened at $16.10 on Friday. The company has a quick ratio of 13.29, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of -10.52 and a beta of 1.47. The business has a fifty day simple moving average of $15.92 and a 200-day simple moving average of $12.20. Centessa Pharmaceuticals has a fifty-two week low of $5.58 and a fifty-two week high of $18.74.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.05. On average, equities analysts forecast that Centessa Pharmaceuticals will post -1.62 EPS for the current fiscal year.

Insider Transactions at Centessa Pharmaceuticals

In related news, insider Gregory M. Weinhoff sold 11,742 shares of Centessa Pharmaceuticals stock in a transaction on Friday, October 25th. The stock was sold at an average price of $15.38, for a total transaction of $180,591.96. Following the completion of the sale, the insider now directly owns 183,266 shares of the company’s stock, valued at $2,818,631.08. The trade was a 6.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Saurabh Saha sold 175,000 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $16.52, for a total value of $2,891,000.00. Following the completion of the transaction, the chief executive officer now directly owns 776,924 shares of the company’s stock, valued at approximately $12,834,784.48. The trade was a 18.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 320,862 shares of company stock worth $5,161,681 over the last 90 days. 11.59% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its holdings in Centessa Pharmaceuticals by 16.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,958,079 shares of the company’s stock worth $33,427,000 after acquiring an additional 418,615 shares in the last quarter. Nantahala Capital Management LLC bought a new stake in Centessa Pharmaceuticals during the second quarter worth about $4,064,000. Driehaus Capital Management LLC raised its holdings in Centessa Pharmaceuticals by 89.5% during the second quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock worth $18,891,000 after acquiring an additional 987,997 shares in the last quarter. GSA Capital Partners LLP raised its holdings in Centessa Pharmaceuticals by 66.1% during the third quarter. GSA Capital Partners LLP now owns 93,658 shares of the company’s stock worth $1,498,000 after acquiring an additional 37,275 shares in the last quarter. Finally, First Light Asset Management LLC raised its holdings in Centessa Pharmaceuticals by 59.2% during the second quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock worth $43,168,000 after acquiring an additional 1,778,515 shares in the last quarter. 82.01% of the stock is owned by institutional investors and hedge funds.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.